Remotely Supervised tDCS+ for Complex Attention in mTBI (Cognetric)

Last updated: November 7, 2025
Sponsor: United States Naval Medical Center, San Diego
Overall Status: Active - Recruiting

Phase

N/A

Condition

Alzheimer's Disease

Memory Loss

Stroke

Treatment

Active tDCS and Cognitive Training Intervention

Sham tDCS and Cognitive Training Intervention

Clinical Study ID

NCT06413173
NMCSD.2023.0048
  • Ages 18-60
  • All Genders

Study Summary

The proposed study will evaluate a new approach to cognitive rehabilitation of mTBI using a brain stimulation technique called "Remotely Supervised Transcranial Direct Current Stimulation combined with Cognitive Training" (RS-tDCS+) which has shown promise for improving complex attention in both healthy and clinical populations. RS-tDCS+ is a home-based, low-risk, non-invasive technique that is designed to boost cognitive training by enhancing learning and the brain's ability to reorganize connections. This study will evaluate RS-tDCS+ for improving complex attention in Active Duty Service Members (ADSM) and Veterans with a history of mTBI. Different tests of complex attention and symptom questionnaires will be used to determine the effects of real versus sham (placebo) RS-tDCS+. Second, the investigators will investigate electrical and connectivity changes in the brain associated with RS-tDCS+ using electroencephalogram (EEG) and magnetic resonance imaging (MRI). Third, the investigators will investigate the lasting effects of any observed changes by evaluating participants at 1 and 6 weeks post-treatment. Lastly, the investigators will explore the impact of individual differences (e.g., PTSD, depression, sleep quality, time since injury, baseline impairment, age, sex, ADSM versus Veteran) on treatment outcome.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. Active-Duty Service Members.

  2. Ages 18 to 60.

  3. All genders.

  4. All racial and ethnic groups.

  5. History of mild TBI (as defined by the DOD/VA criteria used in conjunction with theOSU TBI-ID) sustained at least 3 months and no more than 10 years prior toenrollment.

  6. Self-reported attention and/or concentration difficulties.

  7. At least one cognitive symptom reported on the Neurobehavioral Symptom Inventory (NSI) cognitive subscale.

Exclusion

Exclusion Criteria:

  1. Presence of a medical, psychiatric, physical or non-physical disease, disorder,condition, injury, disability or pre-existent history such that study participation,in the opinion of the PI: (a) may pose a significant risk to the participant; (b)raises the possibility that the participant is unlikely to successfully complete allof the requirements of the study according to the study protocol; or (c) mightadversely impact the integrity of the data or the validity of the study results.Specific conditions include (but are not limited to) a history of: brain tumor,epilepsy, cerebral vascular accident (CVA), Schizophrenia, Bipolar Disorder, andMania.

  2. History of prior treatment with ECT or neuromodulation in the last 12 months.

  3. Current, diagnosed substance dependence.

  4. Newly prescribed medication within the previous 3 weeks.

  5. Diagnosis of intellectual disability or pervasive developmental disorder (i.e.,premorbid IQ less than or equal to 70).

  6. Any medical condition or treatment other than mild TBI (e.g., stroke, tumor, HIV,moderate-severe TBI), with significant neurological disorder or insults that, basedon the Principal Investigator's judgment, would impact risk.

  7. Psychosis or mania within 30 days of enrollment, as determined by the PI, based on apsychiatric history and examination and/or a review of available medical records

  8. Contraindications for tDCS (e.g., metallic cranial plates/screws or implanteddevice, eczema or skin lesions on scalp)

  9. A positive pregnancy report.

Study Design

Total Participants: 160
Treatment Group(s): 2
Primary Treatment: Active tDCS and Cognitive Training Intervention
Phase:
Study Start date:
July 25, 2024
Estimated Completion Date:
September 30, 2028

Study Description

Objectives:

Attention, concentration, and working memory (i.e., complex attention) deficits are the most reported neurocognitive sequelae of mild traumatic brain injury (mTBI) and have been associated with patterns of decreased neural activation. Existing cognitive rehabilitation interventions require significant time and effort and are limited by small-to-moderate effect sizes and uncertain durability/generalization of effects. Novel, neuroplasticity-based interventions that improve complex attention and can be administered remotely are needed to increase access to care, decrease recovery time, and improve outcomes and quality of life following mTBI. This multi-site study will investigate remotely-supervised tDCS (RS-tDCS) combined with cognitive training in the chronic phase of recovery (≥3 months) from mTBI to 1) increase accessibility to care, 2) improve cognitive functioning, post-concussion symptom outcomes, and quality of life and 3) investigate the durability of the intervention in Active Duty Service Members (ADSM; at the Naval Medical Center San Diego (NMCSD) and Veterans (at the Minneapolis VA Health care System (MVAHCS)).

Research Plan and Methods:

This is a double-blind, randomized, sham-controlled study. 80 Veterans from the MVAHCS and 80 ADSM from NMCSD (total N=160) will be recruited. Participants will have a history of mTBI and self-reported attention and/or concentration difficulties. Baseline assessment will include self-reported symptoms and objective neurocognitive performance. Resting state functional connectivity changes will be measured with functional magnetic resonance imaging (fMRI) and oscillatory brain activity will be measured with EEG, both collected at baseline and at post-intervention assessments. Participants will be randomized to either active RS-tDCS or sham RS-tDCS, using stratified randomization by baseline cognitive scores. The intervention sessions will occur in the participant's home, 10 sessions within 2 weeks. Two post-intervention assessments, mirroring the baseline assessment, will occur approximately 1 week and 6 weeks after the intervention. Additionally, the investigators will collect longitudinal real-time data, daily, on TBI symptoms, cognitive, and mood factors during the 6 weeks post-intervention using Ecological Momentary Assessment (EMA).

Clinical Relevance:

RS-tDCS+ addresses two major obstacles of current TBI treatments: Accessibility and adherence. RS-tDCS+ offers several benefits as it can be monitored remotely, and can be self-administered in the home after the first session. If RS-tDCS proves effective, this non-invasive intervention could dramatically improve access to a validated treatment that can be rapidly implemented within various DOD and VA settings to reduce TBI-related symptoms, improve cognition, enhance recovery, bolster occupational performance, and improve quality of life.

Connect with a study center

  • Naval Medical Center San Diego

    San Diego, California 92134
    United States

    Site Not Available

  • Naval Medical Center San Diego

    San Diego 5391811, California 5332921 92134
    United States

    Active - Recruiting

  • Minneapolis VA Health Case System

    Minneapolis, Minnesota 55417
    United States

    Site Not Available

  • Minneapolis VA Health Case System

    Minneapolis 5037649, Minnesota 5037779 55417
    United States

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.